United States of America, Plaintiff/appellee/cross-Appellant v. Mark Thierman, Defendant-Appellant/cross-Appellee. United States of America v. Amino Discounters, Inc., Mark Thierman, United States of America v. Mark Thierman

76 F.3d 390, 1996 U.S. App. LEXIS 7411
CourtCourt of Appeals for the Ninth Circuit
DecidedJanuary 18, 1996
Docket94-10279
StatusUnpublished

This text of 76 F.3d 390 (United States of America, Plaintiff/appellee/cross-Appellant v. Mark Thierman, Defendant-Appellant/cross-Appellee. United States of America v. Amino Discounters, Inc., Mark Thierman, United States of America v. Mark Thierman) is published on Counsel Stack Legal Research, covering Court of Appeals for the Ninth Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
United States of America, Plaintiff/appellee/cross-Appellant v. Mark Thierman, Defendant-Appellant/cross-Appellee. United States of America v. Amino Discounters, Inc., Mark Thierman, United States of America v. Mark Thierman, 76 F.3d 390, 1996 U.S. App. LEXIS 7411 (9th Cir. 1996).

Opinion

76 F.3d 390

NOTICE: Ninth Circuit Rule 36-3 provides that dispositions other than opinions or orders designated for publication are not precedential and should not be cited except when relevant under the doctrines of law of the case, res judicata, or collateral estoppel.
UNITED STATES of America, Plaintiff/Appellee/Cross-Appellant,
v.
Mark THIERMAN, Defendant-Appellant/Cross-Appellee.
UNITED STATES of America, Plaintiff-Appellee,
v.
AMINO DISCOUNTERS, INC., Mark Thierman, et al.,
Defendants-Appellants.
UNITED STATES of America, Plaintiff-Appellant,
v.
Mark THIERMAN, Defendant-Appellee.

Nos. 94-10279, 94-10293, 94-10307.

United States Court of Appeals, Ninth Circuit.

Argued and Submitted Oct. 17, 1995.
Filed Nov. 13, 1995.
Amended Jan. 18, 1996.

Before: GOODWIN and HAWKINS, Circuit Judges, and FITZGERALD,* District Judge.

ORDER

With the filing of the amended memorandum, the panel votes unanimously to deny both petitions for rehearing in this matter.

Before: GOODWIN and HAWKINS, Circuit Judges, and FITZGERALD,* District Judge.

AMENDED MEMORANDUM**

Mark Thierman appeals his convictions under the FFDCA for one count of misbranding drugs with the intent to defraud or mislead consumers or the FDA, and two counts of conspiracy to violate the FFDCA with the intent to defraud or mislead consumers or the FDA. The issues on appeal include denial of his motion to sever his indictments for trial; prosecutorial misconduct; Fed.R.Evid. 403 & 404(b) error in the admission of "other bad acts" evidence; admission of evidence gathered pursuant to an invalid warrant; failure to instruct the jury on "current good manufacturing practices," an element charged in both conspiracies; failure to instruct the jury on the unanimity requirement for several of their findings; and insufficient evidence to support the verdicts.

The government filed a cross-appeal asserting that the district court failed to adjust Thierman's status under the sentencing guidelines using a fraud "loss enhancement" based on Thierman's profits. We do not reach the cross appeal because errors in the trial require reversal and remand for a new trial.

FACTS AND PROCEDURAL BACKGROUND

Thierman first began to manufacture and sell a substance called "GHB" in September of 1989. He promoted GHB as a drug, advertising in magazines such as Muscle and Fitness and Ironman. The government first charged Thierman in March of 1992 with (1) conspiracy to violate the FFDCA between December 1989 and March 1991, (2) operating an unregistered drug manufacturing facility, (3) introducing a misbranded drug into interstate commerce, and (4) introducing an unapproved new drug into interstate commerce.

After this indictment, Thierman set up two new facilities for the manufacture of GHB. He continued to sell GHB manufactured at these facilities, but now labeled it only "GHB," and did not explicitly make any claims as to its effects. One of the facilities was destroyed by fire in July of 1992, and the other facility also experienced a fire in October of 1992.

The government then brought a second indictment charging Thierman with (1) conspiracy to violate the FFDCA between May 1991 and October 1992, (2) operating an unregistered drug manufacturing facility, (3) introducing an adulterated drug into interstate commerce, and (4) introducing a misbranded drug into interstate commerce.

In August of 1993 the court joined the two indictments for trial over Thierman's protest that he would be forced to present inconsistent defenses (defending the first indictment by asserting he was open and honest about the drug effects of GHB, and thus did not intend to defraud or mislead consumers or the FDA; and defending the second indictment by asserting that he did not sell the GHB as a drug).

After a three week trial, a jury convicted Thierman on one count of misbranding from the first indictment, and both counts of conspiracy.

DISCUSSION

I. Defendant's Motion to Sever

Because Thierman challenges the joinder of his two indictments for trial as prejudicial, we must determine whether, in failing to grant the motion for severance, the court abused its discretion. See U.S. v. Vasquez-Velasco, 15 F.3d 833, 844 (9th Cir.1993).

(A) Thierman argues that this challenge falls under Fed.R.Crim.P. 8(a), but it more accurately falls under Fed.R.Crim.P. 14. Both of Thierman's objections assert that prejudice resulted from joinder--a topic appropriate to Rule 14, not Rule 8(a).1

To establish prejudice under Vasquez-Velasco, a defendant must show such " 'clear,' 'manifest,' or 'undue' prejudice from the joint trial, that it violates one of his substantive rights, so that the prejudice is of such a magnitude that the defendant was denied a fair trial." Vasquez-Velasco, 15 F.3d at 845-846.

Thierman claims that joinder was prejudicial because (1) it forced him to present antagonistic defenses, and (2) it required the jury to "compartmentalize" evidence admitted for only one of the two counts in a case far too complex for it do so.

Joinder did not force Thierman to present antagonistic defenses. Truly mutually exclusive defenses are "said to exist when acquittal of one co-defendant would necessarily call for conviction of the other." U.S. v. Tootick, 952 F.2d 1078, 1081 (9th Cir.1991). For a single defendant in a multi-count indictment to be forced to assert mutually inconsistent or antagonistic defenses, the charging language would have to be of such a nature that one count could be defended only by proving facts, which if found by the jury to be true, would necessarily convict him on another count. This kind of compulsion was not present here.

The jury could have found that Thierman had no intent to defraud or mislead during the time period of the first count, and that there was no sale for intended drug use during the time period charged in the second count. The defenses are not mutually exclusive. The shifting claims that GHB was sold as a drug at one time and that it was not sold as a drug at another time may cast some doubt on Thierman's veracity, but these claims do not necessarily prove that the product ever was sold as a drug or that it never was sold as a drug.

Thierman found himself wishing to prove that he did not intend to defraud or mislead in one indictment because he openly manufactured GHB and promoted its drug effects to his customers. He was understandably unhappy about having to try to prove in the same trial, before the same jury, that he had not, during the time period charged in the second indictment, sold as a drug, the product he admitted to selling as a drug during the time period of the first indictment.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Chapman v. California
386 U.S. 18 (Supreme Court, 1967)
Harrington v. California
395 U.S. 250 (Supreme Court, 1969)
United States v. Leon
468 U.S. 897 (Supreme Court, 1984)
United States v. Young
470 U.S. 1 (Supreme Court, 1985)
United States v. Attilio Joe Spagnuolo
515 F.2d 818 (Ninth Circuit, 1975)
United States v. Robert Castillo, Jr.
615 F.2d 878 (Ninth Circuit, 1980)
United States v. Jose Robert Gomez-Soto
723 F.2d 649 (Ninth Circuit, 1984)
United States v. Adrian Norman Payseno
782 F.2d 832 (Ninth Circuit, 1986)
United States v. Gregory Lewis
787 F.2d 1318 (Ninth Circuit, 1986)
United States v. George Mostella
802 F.2d 358 (Ninth Circuit, 1986)
United States v. Ara Michaelian
803 F.2d 1042 (Ninth Circuit, 1986)
United States v. Victor Montano Disla
805 F.2d 1340 (Ninth Circuit, 1986)
John K. Lincoln v. Franklin Y.K. Sunn
807 F.2d 805 (Ninth Circuit, 1987)
United States v. David W. Stubbs
873 F.2d 210 (Ninth Circuit, 1989)
United States v. Donaciano Hernandez-Escarsega
886 F.2d 1560 (Ninth Circuit, 1989)
United States v. Joseph Sehnal
930 F.2d 1420 (Ninth Circuit, 1991)

Cite This Page — Counsel Stack

Bluebook (online)
76 F.3d 390, 1996 U.S. App. LEXIS 7411, Counsel Stack Legal Research, https://law.counselstack.com/opinion/united-states-of-america-plaintiffappelleecross-appellant-v-mark-ca9-1996.